FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021103861> ?p ?o ?g. }

• W2021103861 endingPage "630" @default.
• W2021103861 startingPage "627" @default.
• W2021103861 abstract "Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 micrograms of the somatostatin analogue Sandostatin (SMS 201-995). All patients had an extensive tumour load and 13 were pretreated with chemotherapy. Before Sandostatin treatment the patients with pancreatic cancer showed a higher mean plasma concentration of GH (P less than 0.05) and a lower concentration of 'total' somatomedin-C (P less than 0.005) compared with patients with colorectal cancer; there was no significant difference between these two groups in plasma levels of directly assayable somatomedin-C, EGF/TGF-alpha, insulin and prolactin. Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks. Plasma insulin levels also were suppressed but only during the first 3-5 days of treatment. Plasma EGF-TGF-alpha levels increased significantly at day 5 of treatment only in the pancreatic cancer patients. Twenty-seven per cent of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects. However, the overall survival remained disappointing, emphasising the need for better treatment regimens." @default.
• W2021103861 created "2016-06-24" @default.
• W2021103861 creator A5003346246 @default.
• W2021103861 creator A5013017255 @default.
• W2021103861 creator A5024516181 @default.
• W2021103861 creator A5053613815 @default.
• W2021103861 creator A5062762892 @default.
• W2021103861 creator A5069964093 @default.
• W2021103861 creator A5082363986 @default.
• W2021103861 creator A5090377433 @default.
• W2021103861 date "1990-10-01" @default.
• W2021103861 modified "2023-10-10" @default.
• W2021103861 title "Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects" @default.
• W2021103861 cites W1559045450 @default.
• W2021103861 cites W1578846086 @default.
• W2021103861 cites W1656900923 @default.
• W2021103861 cites W1986807640 @default.
• W2021103861 cites W1995956817 @default.
• W2021103861 cites W2008760160 @default.
• W2021103861 cites W2017032375 @default.
• W2021103861 cites W2025313999 @default.
• W2021103861 cites W2076565277 @default.
• W2021103861 cites W2084931137 @default.
• W2021103861 cites W2091588312 @default.
• W2021103861 cites W2148430251 @default.
• W2021103861 cites W2406709103 @default.
• W2021103861 cites W4239520211 @default.
• W2021103861 doi "https://doi.org/10.1038/bjc.1990.343" @default.
• W2021103861 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1971491" @default.
• W2021103861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1977468" @default.
• W2021103861 hasPublicationYear "1990" @default.
• W2021103861 type Work @default.
• W2021103861 sameAs 2021103861 @default.
• W2021103861 citedByCount "85" @default.
• W2021103861 countsByYear W20211038612013 @default.
• W2021103861 countsByYear W20211038612014 @default.
• W2021103861 countsByYear W20211038612015 @default.
• W2021103861 countsByYear W20211038612017 @default.
• W2021103861 countsByYear W20211038612019 @default.
• W2021103861 crossrefType "journal-article" @default.
• W2021103861 hasAuthorship W2021103861A5003346246 @default.
• W2021103861 hasAuthorship W2021103861A5013017255 @default.
• W2021103861 hasAuthorship W2021103861A5024516181 @default.
• W2021103861 hasAuthorship W2021103861A5053613815 @default.
• W2021103861 hasAuthorship W2021103861A5062762892 @default.
• W2021103861 hasAuthorship W2021103861A5069964093 @default.
• W2021103861 hasAuthorship W2021103861A5082363986 @default.
• W2021103861 hasAuthorship W2021103861A5090377433 @default.
• W2021103861 hasBestOaLocation W20211038611 @default.
• W2021103861 hasConcept C121608353 @default.
• W2021103861 hasConcept C126322002 @default.
• W2021103861 hasConcept C134018914 @default.
• W2021103861 hasConcept C2776297358 @default.
• W2021103861 hasConcept C2776694085 @default.
• W2021103861 hasConcept C2778024521 @default.
• W2021103861 hasConcept C2779064019 @default.
• W2021103861 hasConcept C2779306644 @default.
• W2021103861 hasConcept C2780210213 @default.
• W2021103861 hasConcept C2780512811 @default.
• W2021103861 hasConcept C2984496839 @default.
• W2021103861 hasConcept C46699223 @default.
• W2021103861 hasConcept C526805850 @default.
• W2021103861 hasConcept C542804219 @default.
• W2021103861 hasConcept C71315377 @default.
• W2021103861 hasConcept C71924100 @default.
• W2021103861 hasConcept C80862487 @default.
• W2021103861 hasConcept C90924648 @default.
• W2021103861 hasConceptScore W2021103861C121608353 @default.
• W2021103861 hasConceptScore W2021103861C126322002 @default.
• W2021103861 hasConceptScore W2021103861C134018914 @default.
• W2021103861 hasConceptScore W2021103861C2776297358 @default.
• W2021103861 hasConceptScore W2021103861C2776694085 @default.
• W2021103861 hasConceptScore W2021103861C2778024521 @default.
• W2021103861 hasConceptScore W2021103861C2779064019 @default.
• W2021103861 hasConceptScore W2021103861C2779306644 @default.
• W2021103861 hasConceptScore W2021103861C2780210213 @default.
• W2021103861 hasConceptScore W2021103861C2780512811 @default.
• W2021103861 hasConceptScore W2021103861C2984496839 @default.
• W2021103861 hasConceptScore W2021103861C46699223 @default.
• W2021103861 hasConceptScore W2021103861C526805850 @default.
• W2021103861 hasConceptScore W2021103861C542804219 @default.
• W2021103861 hasConceptScore W2021103861C71315377 @default.
• W2021103861 hasConceptScore W2021103861C71924100 @default.
• W2021103861 hasConceptScore W2021103861C80862487 @default.
• W2021103861 hasConceptScore W2021103861C90924648 @default.
• W2021103861 hasIssue "4" @default.
• W2021103861 hasLocation W20211038611 @default.
• W2021103861 hasLocation W20211038612 @default.
• W2021103861 hasLocation W20211038613 @default.
• W2021103861 hasLocation W20211038614 @default.
• W2021103861 hasOpenAccess W2021103861 @default.
• W2021103861 hasPrimaryLocation W20211038611 @default.
• W2021103861 hasRelatedWork W1585166224 @default.
• W2021103861 hasRelatedWork W1996607479 @default.
• W2021103861 hasRelatedWork W2033991754 @default.
• W2021103861 hasRelatedWork W2048918946 @default.
• W2021103861 hasRelatedWork W2050730962 @default.
• W2021103861 hasRelatedWork W2070076315 @default.

• next